<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="c4caf469-f684-4f6d-98e8-b6a2fff1de98"><labelDrug name="Betapace"><Normalization><mmtx cui="C0728751" preferredWord="Betapace" semType="phsu, orch"/></Normalization></labelDrug><generic name="Sotalol Hydrochloride"/><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.1" text="Drug Label for drug brand Betapace, containing Sotalol Hydrochloride." type="negative"><entity charOffset="0:19" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.1.e.0" text="drug drug" type="Biomedical_Entity"><Normalization><mmtx cui="C0013231" phraseText="Drug Label for drug brand Betapace," preferredWord="Drugs, Non-Prescription" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="47:68" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.1.e.1" text="sotalol hydrochloride" type="Biomedical_Entity"><Normalization><mmtx cui="C0026289" phraseText="Sotalol Hydrochloride." preferredWord="Sotalol Hydrochloride" semType="phsu, orch"/><RxNorm RxCui="7008"/></Normalization></entity><entity charOffset="26:34" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.1.e.2" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="Drug Label for drug brand Betapace," preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.1.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.1.e.1"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.1.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.1.e.2"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.1.e.2" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.1.e.1"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.5" text="Sotalol is also indicated for the maintenance of normal sinus rhythm delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL) in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name Betapace AF. " type="negative"><entity charOffset="0:7" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.5.e.0" text="sotalol" type="Biomedical_Entity"><Normalization><mmtx cui="C0037707" phraseText="Sotalol" preferredWord="Sotalol" semType="phsu, orch"/><RxNorm RxCui="7008"/></Normalization></entity><entity charOffset="255:266" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.5.e.1" text="betapace af" type="Biomedical_Entity"><Normalization><mmtx cui="C0875976" phraseText="marketed under the brand name Betapace AF." preferredWord="Betapace AF" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.5.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.5.e.1"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.6" text="Betapace is not approved for the AFIB/AFL indication and should not be substituted for Betapace AF because only Betapace AF is distributed with a patient package insert that is appropriate for patients with AFIB/AFL." type="negative"><entity charOffset="87:98" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.6.e.0" text="betapace af" type="Biomedical_Entity"><Normalization><mmtx cui="C0875976" phraseText="substituted for Betapace AF" preferredWord="Betapace AF" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="0:8" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.6.e.1" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="112:123" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.6.e.2" text="betapace af" type="Biomedical_Entity"><Normalization><mmtx cui="C0875976" phraseText="only Betapace AF" preferredWord="Betapace AF" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.6.e.1" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.6.e.0"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.6.e.1" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.6.e.2"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.8" text="Betapace (sotalol hydrochloride) is contraindicated in patients with bronchial asthma, sinus bradycardia, second and third degree AV block, unless a functioning pacemaker is present, congenital or acquired long QT syndromes, cardiogenic shock, uncontrolled congestive heart failure, and previous evidence of hypersensitivity to Betapace." type="negative"><entity charOffset="0:8" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.8.e.0" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="328:336" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.8.e.1" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="to Betapace." preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="10:31" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.8.e.2" text="sotalol hydrochloride" type="Biomedical_Entity"><Normalization><mmtx cui="C0026289" phraseText="(sotalol hydrochloride" preferredWord="Sotalol Hydrochloride" semType="phsu, orch"/><RxNorm RxCui="7008"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.8.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.8.e.2"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.8.e.2" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.8.e.1"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.12" text="Patients in CAST I were randomized to receive placebo or individually optimized doses of encainide, flecainide, or moricizine. " type="negative"><entity charOffset="89:98" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.12.e.0" text="encainide" type="Biomedical_Entity"><Normalization><mmtx cui="C0085251" phraseText="individually optimized doses of encainide," preferredWord="Encainide" semType="phsu, orch"/><RxNorm RxCui="281189"/></Normalization></entity><entity charOffset="100:110" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.12.e.1" text="flecainide" type="Biomedical_Entity"><Normalization><mmtx cui="C0016229" phraseText="flecainide," preferredWord="Flecainide" semType="phsu, orch"/><RxNorm RxCui="4441"/></Normalization></entity><entity charOffset="115:125" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.12.e.2" text="moricizine" type="Biomedical_Entity"><Normalization><mmtx cui="C0079856" phraseText="moricizine." preferredWord="Moricizine" semType="phsu, orch"/><RxNorm RxCui="40169"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.12.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.12.e.1"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.12.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.12.e.2"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.12.e.1" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.12.e.2"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.15" text="As compared to placebo treatment, all three active therapies were associated with increases in short-term (14-day) mortality, and encainide and flecainide were associated with significant increases in longer-term mortality as well. " type="negative"><entity charOffset="144:154" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.15.e.0" text="flecainide" type="Biomedical_Entity"><Normalization><mmtx cui="C0016229" phraseText="flecainide" preferredWord="Flecainide" semType="phsu, orch"/><RxNorm RxCui="4441"/></Normalization></entity><entity charOffset="130:139" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.15.e.1" text="encainide" type="Biomedical_Entity"><Normalization><mmtx cui="C0085251" phraseText="encainide" preferredWord="Encainide" semType="phsu, orch"/><RxNorm RxCui="281189"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.15.e.1" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.15.e.0"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.18" text="Betapace (sotalol hydrochloride) is devoid of Class I effects, and in a large (n 1,456) controlled trial in patients with a recent myocardial infarction, who did not necessarily have ventricular arrhythmias, Betapace did not produce increased mortality at doses up to 320 mg/day (see Clinical Studies ). " type="negative"><entity charOffset="208:216" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.18.e.0" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="0:8" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.18.e.1" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="10:31" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.18.e.2" text="sotalol hydrochloride" type="Biomedical_Entity"><Normalization><mmtx cui="C0026289" phraseText="(sotalol hydrochloride" preferredWord="Sotalol Hydrochloride" semType="phsu, orch"/><RxNorm RxCui="7008"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.18.e.2" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.18.e.0"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.18.e.1" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.18.e.2"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.21" text="Like other antiarrhythmic agents, Betapace can provoke new or worsened ventricular arrhythmias in some patients, including sustained ventricular tachycardia or ventricular fibrillation, with potentially fatal consequences. " type="negative"><entity charOffset="11:32" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.21.e.0" text="antiarrhythmic agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003195" phraseText="Like other antiarrhythmic agents," preferredWord="Anti-Arrhythmia Agents" semType="phsu"/><RxNorm RxCui="883"/></Normalization></entity><entity charOffset="34:42" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.21.e.1" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.21.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.21.e.1"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.23" text="The risk of Torsade de Pointes progressively increases with prolongation of the QT interval, and is worsened also by reduction in heart rate and reduction in serum potassium (see Electrolyte Disturbances)." type="negative"><entity charOffset="164:173" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.23.e.0" text="potassium" type="Biomedical_Entity"><Normalization><mmtx cui="C0597277" phraseText="reduction in serum potassium" preferredWord="Potassium Ion" semType="phsu, elii"/><RxNorm RxCui="8588"/></Normalization></entity><entity charOffset="179:190" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.23.e.1" text="electrolyte" type="Biomedical_Entity"><Normalization><mmtx cui="C3536863" phraseText="Electrolyte Disturbances" preferredWord="Electrolyte [EPC]" semType="phsu"/><RxNorm RxCui="3793"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.23.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.23.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50" lineNumber="36" text="In patients who have congestive heart failure controlled by digitalis and/or diuretics, Betapace should be administered cautiously. " type="regular"><entity charOffset="107:130" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.0" text="administered cautiously" type="Caution_Interaction"/><entity charOffset="88:96" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.2" text="Betapace" type="Drug"><Normalization><mmtx cui="C0728751" phraseText="Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="21:45" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.3" text="congestive heart failure" type="SPAN"><Normalization><mmtx cui="C0018802" phraseText="congestive heart failure" preferredWord="Congestive heart failure" semType="dsyn"/></Normalization></entity><entity charOffset="60:69" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.4" text="digitalis" type="Drug"><Normalization><mmtx cui="C0304520" phraseText="controlled by digitalis" preferredWord="Digitalis preparation" semType="phsu, carb"/><RxNorm RxCui="91235"/></Normalization></entity><entity charOffset="77:86" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.5" text="diuretics" type="Drug_Class"><Normalization><mmtx cui="C0012798" phraseText="diuretics," preferredWord="Diuretics" semType="phsu"/><RxNorm RxCui="3567"/></Normalization></entity><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.0"><relations><relation type="hasContext"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.5"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.3" ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.4" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.2" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.0" type="Caution_Interaction"/><pair context="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.3" ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.5" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.2" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.0" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.4" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.50.e.5"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.51" text="Both digitalis and sotalol slow AV conduction. " type="negative"><entity charOffset="5:14" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.51.e.0" text="digitalis" type="Biomedical_Entity"><Normalization><mmtx cui="C0304520" phraseText="Both digitalis" preferredWord="Digitalis preparation" semType="phsu, carb"/><RxNorm RxCui="91235"/></Normalization></entity><entity charOffset="19:26" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.51.e.1" text="sotalol" type="Biomedical_Entity"><Normalization><mmtx cui="C0037707" phraseText="sotalol slow AV conduction." preferredWord="Sotalol" semType="phsu, orch"/><RxNorm RxCui="7008"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.51.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.51.e.1"/></sentence><sentence biomedicalEntities="1" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.59" lineNumber="40" text="Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs." type="irregular"><entity charOffset="0:17" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.59.e.0" text="Special attention" type="Caution_Interaction"/><entity charOffset="159:173" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.59.e.2" text="diuretic drugs" type="Drug_Class"><Normalization><mmtx cui="C0012798" phraseText="concomitant diuretic drugs." preferredWord="Diuretics" semType="phsu"/><mmtx cui="C0013227" phraseText="concomitant diuretic drugs." preferredWord="Pharmaceutical Preparations" semType="phsu"/><RxNorm RxCui="3567"/></Normalization></entity><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.59.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.59.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.59.e.2"/></relation><relation type="hasObject"><labelDrug text="Betapace"/><normalization><mmtx><preferredWord>Betapace</preferredWord><phraseText>Betapace</phraseText><cuiCode>C0728751</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.59.e.2"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.72" text="Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy. " type="negative"><entity charOffset="20:34" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.72.e.0" text="catecholamines" type="Biomedical_Entity"><Normalization><mmtx cui="C0007412" phraseText="Hypersensitivity to catecholamines" preferredWord="Catecholamines" semType="phsu, nsba"/><RxNorm RxCui="2146"/></Normalization></entity><entity charOffset="80:92" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.72.e.1" text="beta-blocker" type="Biomedical_Entity"><Normalization><mmtx cui="C0001645" phraseText="withdrawn from beta-blocker therapy." preferredWord="Adrenergic beta-Antagonists" semType="phsu"/><RxNorm RxCui="371"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.72.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.72.e.1"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.74" text="Therefore, it is prudent when discontinuing chronically administered Betapace, particularly in patients with ischemic heart disease, to carefully monitor the patient and consider the temporary use of an alternate betablocker if appropriate. " type="negative"><entity charOffset="213:224" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.74.e.0" text="betablocker" type="Biomedical_Entity"><Normalization><mmtx cui="C0001645" phraseText="the temporary use of an alternate betablocker" preferredWord="Adrenergic beta-Antagonists" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="69:77" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.74.e.1" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="chronically administered Betapace," preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.74.e.1" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.74.e.0"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.81" text="It is prudent, if Betapace (sotalol hydrochloride) is to be administered, to use the smallest effective dose, so that inhibition of bronchodilation produced by endogenous or exogenous catecholamine stimulation of beta 2 receptors may be minimized." type="negative"><entity charOffset="184:197" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.81.e.0" text="catecholamine" type="Biomedical_Entity"><Normalization><mmtx cui="C0007412" phraseText="exogenous catecholamine stimulation of beta 2 receptors" preferredWord="Catecholamines" semType="phsu, nsba"/><RxNorm RxCui="2146"/></Normalization></entity><entity charOffset="28:49" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.81.e.1" text="sotalol hydrochloride" type="Biomedical_Entity"><Normalization><mmtx cui="C0026289" phraseText="(sotalol hydrochloride" preferredWord="Sotalol Hydrochloride" semType="phsu, orch"/><RxNorm RxCui="7008"/></Normalization></entity><entity charOffset="18:26" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.81.e.2" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.81.e.1" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.81.e.0"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.81.e.2" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.81.e.0"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.81.e.2" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.81.e.1"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.83" text="While taking beta-blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. " type="negative"><entity charOffset="13:26" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.83.e.0" text="beta-blockers" type="Biomedical_Entity"><Normalization><mmtx cui="C0001645" phraseText="taking beta-blockers," preferredWord="Adrenergic beta-Antagonists" semType="phsu"/><RxNorm RxCui="371"/></Normalization></entity><entity charOffset="93:102" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.83.e.1" text="allergens" type="Biomedical_Entity"><Normalization><mmtx cui="C3274161" phraseText="of allergens" preferredWord="Allergen (brand of diphenylpyraline)" semType="phsu, orch"/><RxNorm RxCui="1297244"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.83.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.83.e.1"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.88" text="In patients with diabetes (especially labile diabetes) or with a history of episodes of spontaneous hypoglycemia, Betapace should be given with caution since beta-blockade may mask some important premonitory signs of acute hypoglycemia, e.g., tachycardia." type="negative"><entity charOffset="114:122" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.88.e.0" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="163:171" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.88.e.1" text="blockade" type="Biomedical_Entity"><Normalization><mmtx cui="C3540676" phraseText="beta-blockade" preferredWord="Blockade" semType="phsu"/><RxNorm RxCui="1423936"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.88.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.88.e.1"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.96" text="Betapace ( sotalol hydrochloride) is mainly eliminated via the kidneys through glomerular filtration and to a small degree by tubular secretion. " type="negative"><entity charOffset="11:32" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.96.e.0" text="sotalol hydrochloride" type="Biomedical_Entity"><Normalization><mmtx cui="C0026289" phraseText="( sotalol hydrochloride" preferredWord="Sotalol Hydrochloride" semType="phsu, orch"/><RxNorm RxCui="7008"/></Normalization></entity><entity charOffset="0:8" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.96.e.1" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.96.e.1" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.96.e.0"/></sentence><sentence biomedicalEntities="7" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104" lineNumber="96" text="Class Ia antiarrhythmic drugs, such as disopyramide, quinidine and procainamide and other Class III drugs (e.g., amiodarone) are not recommended as concomitant therapy with Betapace, because of their potential to prolong refractoriness (see WARNINGS ). " type="regular"><anaphoraRelation><anaphoraEntity charOffset="194:199" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.6" text="their" type="Expression"/><antecedentEntity charOffset="0-29" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.0" text="Class Ia antiarrhythmic drugs" type="Drug_Class"/></anaphoraRelation><anaphoraRelation><anaphoraEntity charOffset="194:199" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.6" text="their" type="Expression"/><antecedentEntity charOffset="90-105" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.4" text="Class III drugs" type="Drug_Class"/></anaphoraRelation><entity charOffset="0:29" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.0" text="Class Ia antiarrhythmic drugs" type="Drug_Class"><Normalization><mmtx cui="C0304503" phraseText="Class Ia antiarrhythmic drugs," preferredWord="Class Ia antiarrhythmic drug" semType="phsu"/><RxNorm RxCui="5716"/></Normalization></entity><entity charOffset="39:51" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.1" text="disopyramide" type="Drug"><Normalization><mmtx cui="C0012702" phraseText="such as disopyramide," preferredWord="Disopyramide" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="53:62" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.2" text="quinidine" type="Drug"><Normalization><mmtx cui="C0034414" phraseText="quinidine" preferredWord="Quinidine" semType="phsu, orch"/><RxNorm RxCui="9068"/></Normalization></entity><entity charOffset="67:79" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.3" text="procainamide" type="Drug"><Normalization><mmtx cui="C0033216" phraseText="procainamide" preferredWord="Procainamide" semType="phsu, orch"/><RxNorm RxCui="155056"/></Normalization></entity><entity charOffset="90:105" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.4" text="Class III drugs" type="Drug_Class"><Normalization><mmtx cui="C0013227" phraseText="other Class III drugs" preferredWord="Pharmaceutical Preparations" semType="phsu"/><RxNorm RxCui="5716"/></Normalization></entity><entity charOffset="113:123" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.5" text="amiodarone" type="Drug"><Normalization><mmtx cui="C0002598" phraseText="amiodarone" preferredWord="Amiodarone" semType="phsu, orch"/><RxNorm RxCui="203114"/></Normalization></entity><entity charOffset="173:181" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.13" text="Betapace" type="Drug"><Normalization><mmtx cui="C0728751" phraseText="with Betapace," preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="213:235" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.14" text="prolong refractoriness" type="Specific_Interaction"/><drugClassMembership drug="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.1" drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.0"/><drugClassMembership drug="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.2" drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.0"/><drugClassMembership drug="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.3" drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.0"/><drugClassMembership drug="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.5" drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.4"/><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.14"><relations><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.6"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.13"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.13" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.6" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.104.e.14" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106" lineNumber="96" text="Additive Class II effects would also be anticipated with the use of other beta-blocking agents concomitantly with Betapace." type="regular"><anaphoraRelation><anaphoraEntity charOffset="74:94" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.e.0" text="beta-blocking agents" type="Expression"/><antecedentEntity charOffset="9-17" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.e.3" text="Class II" type="Drug_Class"/></anaphoraRelation><entity charOffset="0:8|18:25" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.e.1" text="Additive effects" type="Specific_Interaction"/><entity charOffset="9:17" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.e.3" text="Class II" type="Drug_Class"><Normalization><RxNorm RxCui="5716"/></Normalization></entity><entity charOffset="114:122" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.e.5" text="Betapace" type="Drug"><Normalization><mmtx cui="C0728751" phraseText="with Betapace." preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.e.5"/></relation><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.e.3" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.e.5" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.106.e.1" type="Specific_Interaction"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.108" text="Single and multiple doses of Betapace do not substantially affect serum digoxin levels. " type="negative"><entity charOffset="72:79" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.108.e.0" text="digoxin" type="Biomedical_Entity"><Normalization><mmtx cui="C0012265" phraseText="serum digoxin levels." preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><entity charOffset="29:37" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.108.e.1" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="multiple doses of Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.108.e.1" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.108.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109" lineNumber="100" text="Proarrhythmic events were more common in Betapace treated patients also receiving digoxin, it is not clear whether this represents an interaction or is related to the presence of CHF, a known risk factor for proarrhythmia, in the patients receiving digoxin. " type="regular"><entity charOffset="0:20" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.0" text="Proarrhythmic events" type="Specific_Interaction"/><entity charOffset="41:49" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.2" text="Betapace" type="Drug"><Normalization><mmtx cui="C0728751" phraseText="more common in Betapace treated patients also" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="82:89" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.3" text="digoxin" type="Drug"><Normalization><mmtx cui="C0012265" phraseText="digoxin," preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><entity charOffset="179:182" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.4" text="CHF" type="SPAN"><Normalization><mmtx cui="C0018802" phraseText="related to the presence of CHF," preferredWord="Congestive heart failure" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.0"><relations><relation type="hasContext"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.3"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.4" ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.2" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.3" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.109.e.0" type="Specific_Interaction"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.110" text="Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. " type="negative"><entity charOffset="5:25" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.110.e.0" text="digitalis glycosides" type="Biomedical_Entity"><Normalization><mmtx cui="C0012253" phraseText="Both digitalis glycosides" preferredWord="Digitalis Glycosides" semType="phsu, carb"/><RxNorm RxCui="91235"/></Normalization></entity><entity charOffset="30:43" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.110.e.1" text="beta-blockers" type="Biomedical_Entity"><Normalization><mmtx cui="C0001645" phraseText="beta-blockers slow atrioventricular conduction" preferredWord="Adrenergic beta-Antagonists" semType="phsu"/><RxNorm RxCui="371"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.110.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.110.e.1"/></sentence><sentence biomedicalEntities="0" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.111" lineNumber="100" text="Concomitant use can increase the risk of bradycardia." type="irregular"><entity charOffset="41:52" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.111.e.0" text="bradycardia" type="Specific_Interaction"/><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.111.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.111.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.110" text="Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. "><entity charOffset="5:25" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.110.e.0" text="digitalis glycosides" type="Drug_Class"><Normalization><mmtx cui="C0012253" phraseText="Both digitalis glycosides" preferredWord="Digitalis Glycosides" semType="phsu, carb"/></Normalization></entity></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.110" text="Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. "><entity charOffset="30:43" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.110.e.1" text="beta-blockers" type="Drug_Class"><Normalization><mmtx cui="C0001645" phraseText="beta-blockers slow atrioventricular conduction" preferredWord="Adrenergic beta-Antagonists" semType="phsu"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="2" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113" lineNumber="104" text="Betapace should be administered with caution in conjunction with calcium-blocking drugs because of possible additive effects on atrioventricular conduction or ventricular function. " type="regular"><entity charOffset="0:8" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.0" text="Betapace" type="Drug"><Normalization><mmtx cui="C0728751" phraseText="Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="65:87" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.1" text="calcium-blocking drugs" type="Drug_Class"><Normalization><mmtx cui="C0006684" phraseText="in conjunction with calcium-blocking drugs" preferredWord="Calcium Channel Blockers" semType="phsu"/><RxNorm RxCui="1895"/></Normalization></entity><entity charOffset="108:155" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.2" text="additive effects on atrioventricular conduction" type="Specific_Interaction"/><entity charOffset="108:127|159:179" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.4" text="additive effects on ventricular function" type="Specific_Interaction"/><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.2"><relations><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.ddi.2"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.4"><relations><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.1" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="0" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.114" lineNumber="104" text="Additionally, concomitant use of these drugs may have additive effects on blood pressure, possibly leading to hypotension." type="irregular"><entity charOffset="54:88" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.114.e.0" text="additive effects on blood pressure" type="Specific_Interaction"/><entity charOffset="110:121" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.114.e.2" text="hypotension" type="Specific_Interaction"/><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.114.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.114.e.0"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113" text="Betapace should be administered with caution in conjunction with calcium-blocking drugs because of possible additive effects on atrioventricular conduction or ventricular function. "><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.0"/></ellipsisSentence></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113" text="Betapace should be administered with caution in conjunction with calcium-blocking drugs because of possible additive effects on atrioventricular conduction or ventricular function. "><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.1"/></ellipsisSentence></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.114.ddi.2"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.114.e.2"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113" text="Betapace should be administered with caution in conjunction with calcium-blocking drugs because of possible additive effects on atrioventricular conduction or ventricular function. "><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.0"/></ellipsisSentence></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113" text="Betapace should be administered with caution in conjunction with calcium-blocking drugs because of possible additive effects on atrioventricular conduction or ventricular function. "><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.113.e.1"/></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="4" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116" lineNumber="108" text="Concomitant use of catecholamine-depleting drugs, such as reserpine and guanethidine, with a beta-blocker may produce an excessive reduction of resting sympathetic nervous tone. " type="regular"><entity charOffset="19:48" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.0" text="catecholamine-depleting drugs" type="Drug_Class"><Normalization><mmtx cui="C0007412" phraseText="Concomitant use of catecholamine-depleting drugs," preferredWord="Catecholamines" semType="phsu, nsba"/><mmtx cui="C0013227" phraseText="Concomitant use of catecholamine-depleting drugs," preferredWord="Pharmaceutical Preparations" semType="phsu"/><mmtx cui="C3536742" phraseText="Concomitant use of catecholamine-depleting drugs," preferredWord="Catecholamine [EPC]" semType="phsu"/><mmtx cui="C0013227" phraseText="Concomitant use of catecholamine-depleting drugs," preferredWord="Pharmaceutical Preparations" semType="phsu"/><RxNorm RxCui="990350"/></Normalization></entity><entity charOffset="58:67" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.1" text="reserpine" type="Drug"><Normalization><mmtx cui="C0035179" phraseText="such as reserpine" preferredWord="Reserpine" semType="phsu, orch"/><RxNorm RxCui="9260"/></Normalization></entity><entity charOffset="72:84" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.2" text="guanethidine" type="Drug"><Normalization><mmtx cui="C0018318" phraseText="guanethidine," preferredWord="Guanethidine" semType="phsu, orch"/><RxNorm RxCui="5036"/></Normalization></entity><entity charOffset="93:105" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.3" text="beta-blocker" type="Drug_Class"><Normalization><mmtx cui="C0001645" phraseText="with a beta-blocker" preferredWord="Adrenergic beta-Antagonists" semType="phsu"/><RxNorm RxCui="371"/></Normalization></entity><entity charOffset="121:176" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.6" text="excessive reduction of resting sympathetic nervous tone" type="Specific_Interaction"><Normalization><mmtx cui="C0027769" phraseText="an excessive reduction of resting sympathetic nervous tone." preferredWord="Nervousness" semType="sosy"/></Normalization></entity><drugClassMembership drug="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.1" drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.0"/><drugClassMembership drug="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.2" drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.0"/><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.3" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.116.e.6" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117" lineNumber="108" text="Patients treated with Betapace plus a catecholamine depletor should therefore be closely monitored for evidence of hypotension and/or marked bradycardia which may produce syncope." type="regular"><entity charOffset="22:30" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.0" text="Betapace" type="Drug"><Normalization><mmtx cui="C0728751" phraseText="treated with Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="38:60" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.1" text="catecholamine depletor" type="Drug_Class"><Normalization><mmtx cui="C0007412" phraseText="plus a catecholamine depletor" preferredWord="Catecholamines" semType="phsu, nsba"/><mmtx cui="C3536742" phraseText="plus a catecholamine depletor" preferredWord="Catecholamine [EPC]" semType="phsu"/><RxNorm RxCui="1437132"/></Normalization></entity><entity charOffset="115:126" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.2" text="hypotension" type="Specific_Interaction"/><entity charOffset="141:152" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.4" text="bradycardia" type="Specific_Interaction"/><entity charOffset="171:178" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.6" text="syncope" type="Specific_Interaction"><Normalization><mmtx cui="C0039070" phraseText="syncope." preferredWord="Syncope" semType="sosy"/></Normalization></entity><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.2"><relations><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.ddi.2"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.4"><relations><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.ddi.3"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.6"><relations><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.1" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.2" type="Specific_Interaction"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.118" text="Insulin and oral antidiabetics" type="negative"><entity charOffset="0:7" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.118.e.0" text="insulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1579433" phraseText="Insulin" preferredWord="Insulin [EPC]" semType="phsu"/><RxNorm RxCui="5856"/></Normalization></entity><entity charOffset="17:30" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.118.e.1" text="antidiabetics" type="Biomedical_Entity"><Normalization><mmtx cui="C0935929" phraseText="oral antidiabetics" preferredWord="Antidiabetics" semType="phsu"/><RxNorm RxCui="282360"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.118.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.118.e.1"/></sentence><sentence biomedicalEntities="1" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119" lineNumber="112" text="Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. " type="irregular"><anaphoraRelation><antecedentSentence ID="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.118" Text="Insulin and oral antidiabetics"/><anaphoraEntity charOffset="54:72" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.1" text="antidiabetic drugs" type="Expression"/><antecedentEntity charOffset="12:30" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.118.e.0" text="oral antidiabetics" type="Drug_Class"/></anaphoraRelation><entity charOffset="43:50" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.0" text="insulin" type="Drug"><Normalization><mmtx cui="C0021641" phraseText="the dosage of insulin" preferredWord="Insulin" semType="phsu, aapp, horm"/><mmtx cui="C1533581" phraseText="the dosage of insulin" preferredWord="Recombinant Insulin" semType="phsu, aapp, horm"/><mmtx cui="C1579433" phraseText="the dosage of insulin" preferredWord="Insulin [EPC]" semType="phsu"/><RxNorm RxCui="5856"/></Normalization></entity><entity charOffset="0:13" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.2" text="Hyperglycemia" type="Specific_Interaction"><Normalization><mmtx cui="C0020456" phraseText="Hyperglycemia" preferredWord="Hyperglycemia" semType="dsyn"/></Normalization></entity><entity charOffset="33:39|73:95" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.4" text="dosage may require adjustment" type="Caution_Interaction"/><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.2"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117" text="Patients treated with Betapace plus a catecholamine depletor should therefore be closely monitored for evidence of hypotension and/or marked bradycardia which may produce syncope."><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.0"/></ellipsisSentence><middleSentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.118" text="Insulin and oral antidiabetics"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.0"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.ddi.2"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.4"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117" text="Patients treated with Betapace plus a catecholamine depletor should therefore be closely monitored for evidence of hypotension and/or marked bradycardia which may produce syncope."><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.117.e.0"/></ellipsisSentence><middleSentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.118" text="Insulin and oral antidiabetics"/></relation><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.1"/><pair ddi="true" e1="labelDrug" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.1"/><pair ddi="true" e1="labelDrug" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.119.e.0"/></sentence><sentence biomedicalEntities="4" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122" lineNumber="116" text="Beta-agonists such as salbutamol, terbutaline and isoprenaline may have to be administered in increased dosages when used concomitantly with Betapace." type="irregular"><anaphoraRelation><antecedentSentence ID="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.121" Text="Beta-2-receptor stimulants"/><anaphoraEntity charOffset="0:13" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.0" text="Beta-agonists" type="Expression"/><antecedentEntity charOffset="0:26" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.121.e.0" text="Beta-2-receptor stimulants" type="Drug_Class"/></anaphoraRelation><entity charOffset="22:32" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.2" text="salbutamol" type="Drug"><Normalization><mmtx cui="C0001927" phraseText="Beta-agonists such as salbutamol," preferredWord="Albuterol" semType="phsu, orch"/><mmtx cui="C0001927" phraseText="Beta-agonists such as salbutamol," preferredWord="Albuterol" semType="phsu, orch"/><RxNorm RxCui="435"/></Normalization></entity><entity charOffset="34:45" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.3" text="terbutaline" type="Drug"><Normalization><mmtx cui="C0039542" phraseText="terbutaline" preferredWord="Terbutaline" semType="phsu, orch"/><RxNorm RxCui="10368"/></Normalization></entity><entity charOffset="50:62" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.4" text="isoprenaline" type="Drug"><Normalization><mmtx cui="C0022245" phraseText="isoprenaline" preferredWord="Isoproterenol" semType="phsu, orch"/><RxNorm RxCui="6054"/></Normalization></entity><entity charOffset="78:111" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.5" text="administered in increased dosages" type="Decrease_Interaction"/><entity charOffset="141:149" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.7" text="Betapace" type="Drug"><Normalization><mmtx cui="C0728751" phraseText="concomitantly with Betapace." preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><drugClassMembership drug="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.2" drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.0"/><drugClassMembership drug="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.3" drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.0"/><drugClassMembership drug="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.4" drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.0"/><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.5"><relations><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.7"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.7" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.122.e.5" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.124" text="Beta-blocking drugs may potentiate the rebound hypertension sometimes observed after discontinuation of clonidine, therefore, caution is advised when discontinuing clonidine in patients receiving Betapace." type="negative"><entity charOffset="196:204" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.124.e.0" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="Betapace." preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="164:173" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.124.e.1" text="clonidine" type="Biomedical_Entity"><Normalization><mmtx cui="C0009014" phraseText="clonidine in patients" preferredWord="Clonidine" semType="phsu, orch"/><RxNorm RxCui="2599"/></Normalization></entity><entity charOffset="104:113" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.124.e.2" text="clonidine" type="Biomedical_Entity"><Normalization><mmtx cui="C0009014" phraseText="observed after discontinuation of clonidine," preferredWord="Clonidine" semType="phsu, orch"/><RxNorm RxCui="2599"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.124.e.1" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.124.e.0"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.124.e.2" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.124.e.0"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.126" text="No pharmacokinetic interactions were observed with hydrochlorothiazide or warfarin." type="negative"><entity charOffset="51:70" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.126.e.0" text="hydrochlorothiazide" type="Biomedical_Entity"><Normalization><mmtx cui="C0020261" phraseText="observed with hydrochlorothiazide" preferredWord="Hydrochlorothiazide" semType="phsu, orch"/><RxNorm RxCui="5487"/></Normalization></entity><entity charOffset="74:82" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.126.e.1" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="warfarin." preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.126.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.126.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128" lineNumber="128" text="Administration of Betapace within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. " type="regular"><entity charOffset="18:26" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.0" text="Betapace" type="Drug"><Normalization><mmtx cui="C0728751" phraseText="Administration of Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="45:103" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.1" text="antacids containing aluminum oxide and magnesium hydroxide" type="Drug_Class"><Normalization><mmtx cui="C0003138" phraseText="of antacids" preferredWord="Antacids" semType="phsu"/><mmtx cui="C0024476" phraseText="magnesium hydroxide" preferredWord="Magnesium Hydroxide" semType="inch, phsu"/><RxNorm RxCui="863"/></Normalization></entity><entity charOffset="149:166" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.2" text="reduction in Cmax" type="Decrease_Interaction"/><entity charOffset="149:161|171:174" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.4" text="reduction in AUC" type="Decrease_Interaction"/><entity charOffset="230:273" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.6" text="reduction in the bradycardic effect at rest" type="Specific_Interaction"/><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.ddi.2"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.ddi.3"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.1" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.2" type="Decrease_Interaction"/><pair ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.0" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.1" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.6" type="Specific_Interaction"/></sentence><sentence id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.129" text="Administration of the antacid two hours after Betapace has no effect on the pharmacokinetics or pharmacodynamics of sotalol." type="negative"><entity charOffset="116:123" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.129.e.0" text="sotalol" type="Biomedical_Entity"><Normalization><mmtx cui="C0037707" phraseText="pharmacodynamics of sotalol." preferredWord="Sotalol" semType="phsu, orch"/><RxNorm RxCui="7008"/></Normalization></entity><entity charOffset="46:54" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.129.e.1" text="betapace" type="Biomedical_Entity"><Normalization><mmtx cui="C0728751" phraseText="after Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="22:29" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.129.e.2" text="antacid" type="Biomedical_Entity"><Normalization><mmtx cui="C0003216" phraseText="Administration of the antacid two hours" preferredWord="Anti-Ulcer Agent" semType="phsu"/><RxNorm RxCui="863"/></Normalization></entity><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.129.e.1" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.129.e.0"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.129.e.2" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.129.e.0"/><pair ddi="false" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.129.e.2" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.129.e.1"/></sentence><sentence biomedicalEntities="10" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131" lineNumber="132" text="Betapace should be administered with caution in conjunction with other drugs known to prolong the QT interval such as Class I and Class III antiarrhythmic agents, phenothiazines, tricyclic antidepressants, astemizole, bepridil, certain oral macrolides, and certain quinolone antibiotics (see WARNINGS )." type="regular"><entity charOffset="37:44" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.0" text="caution" type="Caution_Interaction"/><entity charOffset="0:8" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.2" text="Betapace" type="Drug"><Normalization><mmtx cui="C0728751" phraseText="Betapace" preferredWord="Betapace" semType="phsu, orch"/><RxNorm RxCui="224909"/></Normalization></entity><entity charOffset="71:109" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.3" text="drugs known to prolong the QT interval" type="Drug_Class"><Normalization><mmtx cui="C0013227" phraseText="in conjunction with other drugs" preferredWord="Pharmaceutical Preparations" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="118:125|140:161" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.4" text="Class I antiarrhythmic agents" type="Drug_Class"><Normalization><mmtx cui="C0360703" phraseText="Class III antiarrhythmic agents," preferredWord="Class III antiarrhythmic drug" semType="phsu"/><RxNorm RxCui="5716"/></Normalization></entity><entity charOffset="130:161" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.5" text="Class III antiarrhythmic agents" type="Drug_Class"><Normalization><mmtx cui="C0360703" phraseText="Class III antiarrhythmic agents," preferredWord="Class III antiarrhythmic drug" semType="phsu"/><RxNorm RxCui="5716"/></Normalization></entity><entity charOffset="163:177" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.6" text="phenothiazines" type="Drug_Class"><Normalization><mmtx cui="C0031434" phraseText="phenothiazines," preferredWord="phenothiazine" semType="phsu, orch"/><mmtx cui="C0031436" phraseText="phenothiazines," preferredWord="Phenothiazines" semType="phsu, orch"/><mmtx cui="C0304370" phraseText="phenothiazines," preferredWord="Phenothiazine derivatives" semType="phsu, orch"/><RxNorm RxCui="1437064"/></Normalization></entity><entity charOffset="179:204" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.7" text="tricyclic antidepressants" type="Drug_Class"><Normalization><mmtx cui="C0003290" phraseText="tricyclic antidepressants," preferredWord="Tricyclic Antidepressive Agents" semType="phsu"/><RxNorm RxCui="928"/></Normalization></entity><entity charOffset="206:216" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.8" text="astemizole" type="Drug"><Normalization><mmtx cui="C0085170" phraseText="astemizole," preferredWord="Astemizole" semType="phsu, orch"/><RxNorm RxCui="42328"/></Normalization></entity><entity charOffset="218:226" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.9" text="bepridil" type="Drug"><Normalization><mmtx cui="C0005116" phraseText="bepridil," preferredWord="Bepridil" semType="phsu, orch"/><RxNorm RxCui="1436"/></Normalization></entity><entity charOffset="236:251" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.10" text="oral macrolides" type="Drug_Class"><Normalization><mmtx cui="C0003240" phraseText="certain oral macrolides," preferredWord="Macrolide Antibiotics" semType="orch, antb"/><mmtx cui="C0282563" phraseText="certain oral macrolides," preferredWord="Macrolides" semType="phsu, orch"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="265:286" id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.11" text="quinolone antibiotics" type="Drug_Class"><Normalization><mmtx cui="C1533693" phraseText="certain quinolone antibiotics" preferredWord="Quinolone Antibacterial Agents" semType="phsu, orch"/><mmtx cui="C0003232" phraseText="certain quinolone antibiotics" preferredWord="Antibiotics" semType="antb"/><RxNorm RxCui="586358"/></Normalization></entity><classClassMembership drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.4"/><classClassMembership drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.5"/><classClassMembership drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.6"/><classClassMembership drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.7"/><drugClassMembership drug="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.8" drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.3"/><drugClassMembership drug="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.9" drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.3"/><classClassMembership drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.10"/><classClassMembership drugClass="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.11"/><drugInteraction id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.ddi.1"><interaction trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.2" e2="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.3" trigger="Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.131.e.0" type="Caution_Interaction"/></sentence><positiveExamples number="15"/><negativeExamples number="36"/></document>